Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Pilot Study to Evaluate Feasibility of Sensory Stimulation With Gamma Frequency Entrainment
Authors not listed
Massachusetts Institute of Technology · 2018
Abstract
Despite the huge healthcare and economic impact of AD, there is still no disease modifying therapeutics available. In fact, the available therapeutics show low efficacy at best in the treatment of cognitive impairment in dementia. Development of a non-invasive medical device that is effective in slowing cognitive impairment is not only revolutionary but also possibly cost- effective. In this study, participants will come to MIT for a 1-day visit and the investigators will evaluate the effects of GENUS in cognitively normal, healthy adults. Investigators will use Electroencephalogram (EEG), Magnetoencephalography (MEG), magnetic resonance imaging (MRI), neuropsychological testing, and blood sampling in subsets of participants to evaluate for biological effects and safety of GENUS stimulation.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-26 MST
Cite this
APA
Anonymous. (2018). Pilot Study to Evaluate Feasibility of Sensory Stimulation With Gamma Frequency Entrainment. <em>Massachusetts Institute of Technology</em>. https://clinicaltrials.gov/study/NCT07496918
Vancouver
Anonymous. Pilot Study to Evaluate Feasibility of Sensory Stimulation With Gamma Frequency Entrainment. Massachusetts Institute of Technology. 2018.
BibTeX
@misc{anon2018PilotS,
title = {Pilot Study to Evaluate Feasibility of Sensory Stimulation With Gamma Frequency Entrainment},
author = {Anonymous},
journal = {Massachusetts Institute of Technology},
year = {2018},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Palo Alto Veterans Institute for Research 2018
Open access · US-GOV
Efficacy of Repetitive Transcranial Magnetic Stimulation for Improvement of Memory in Older Adults With TBI
Ji Yan Biomedical Co., Ltd. 2026
Open access · US-GOV
A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-Escalation Study to Evaluate the Safety and Tolerability of Stemis™ Administered Intravenously in Elderly Subjects With Mild to Moderate Frailty Syndrome
University of South Florida 2021
Open access · US-GOV
Microbiome in Aging Gut and Brain (MiaGB) Study
Universidad de Almeria 2026
Open access · US-GOV
Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain
Merck Sharp & Dohme LLC 2008
Open access · US-GOV
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial, With Placebo Run-In, and an Open-Label Treatment Period, to Evaluate the Performance of the CogState Computerized Neuropsychological Battery and the ADAS-Cog in Generally Cholinesterase-naive AD Patients
Baylor College of Medicine 2022
Open access · US-GOV